What long-term monitoring for secondary cancers is required after Aucatzyl (obecabtagene autoleucel) treatment?

After Aucatzyl (obecabtagene autoleucel) treatment, patients should be monitored lifelong for signs of secondary malignancies, and if one occurs, the company should be contacted for instructions on collecting patient samples for testing.